Electronic Design Automation (EDA) Software
Electronic design automation (EDA), also referred to as electronic computer-aided design (ECAD), ... Read More
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Lysosomal Storage Diseases 1.2.3 Diabetes 1.2.4 Obesity 1.2.5 Inherited Metabolic Disorders 1.2.6 Hypercholesterolemia 1.3 Market by Application 1.3.1 Global Metabolic Disorder Therapeutics Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Oral 1.3.3 Parenteral 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Metabolic Disorder Therapeutics Market Perspective (2016-2027) 2.2 Metabolic Disorder Therapeutics Growth Trends by Regions 2.2.1 Metabolic Disorder Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Metabolic Disorder Therapeutics Historic Market Share by Regions (2016-2021) 2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2022-2027) 2.3 Metabolic Disorder Therapeutics Industry Dynamic 2.3.1 Metabolic Disorder Therapeutics Market Trends 2.3.2 Metabolic Disorder Therapeutics Market Drivers 2.3.3 Metabolic Disorder Therapeutics Market Challenges 2.3.4 Metabolic Disorder Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue 3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2016-2021) 3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2016-2021) 3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue 3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio 3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2020 3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served 3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service 3.7 Date of Enter into Metabolic Disorder Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Metabolic Disorder Therapeutics Breakdown Data by Type 4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2016-2021) 4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2022-2027) 5 Metabolic Disorder Therapeutics Breakdown Data by Application 5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2016-2021) 5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Metabolic Disorder Therapeutics Market Size (2016-2027) 6.2 North America Metabolic Disorder Therapeutics Market Size by Type 6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) 6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) 6.2.3 North America Metabolic Disorder Therapeutics Market Size by Type (2016-2027) 6.3 North America Metabolic Disorder Therapeutics Market Size by Application 6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) 6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) 6.3.3 North America Metabolic Disorder Therapeutics Market Size by Application (2016-2027) 6.4 North America Metabolic Disorder Therapeutics Market Size by Country 6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) 6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Metabolic Disorder Therapeutics Market Size (2016-2027) 7.2 Europe Metabolic Disorder Therapeutics Market Size by Type 7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2021) 7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2022-2027) 7.2.3 Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2027) 7.3 Europe Metabolic Disorder Therapeutics Market Size by Application 7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2021) 7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2022-2027) 7.3.3 Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2027) 7.4 Europe Metabolic Disorder Therapeutics Market Size by Country 7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country (2016-2021) 7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2016-2027) 8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type 8.2.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2027) 8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application 8.3.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2027) 8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region 8.4.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Metabolic Disorder Therapeutics Market Size (2016-2027) 9.2 Latin America Metabolic Disorder Therapeutics Market Size by Type 9.2.1 Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) 9.2.2 Latin America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) 9.2.3 Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2027) 9.3 Latin America Metabolic Disorder Therapeutics Market Size by Application 9.3.1 Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) 9.3.2 Latin America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) 9.3.3 Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2027) 9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country 9.4.1 Latin America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) 9.4.2 Latin America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2016-2027) 10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type 10.2.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2027) 10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application 10.3.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2027) 10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country 10.4.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Novo Nordisk A/S 11.1.1 Novo Nordisk A/S Company Details 11.1.2 Novo Nordisk A/S Business Overview 11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction 11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.1.5 Novo Nordisk A/S Recent Development 11.2 Sanofi S.A. 11.2.1 Sanofi S.A. Company Details 11.2.2 Sanofi S.A. Business Overview 11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction 11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.2.5 Sanofi S.A. Recent Development 11.3 Boehringer Ingelheim GmbH 11.3.1 Boehringer Ingelheim GmbH Company Details 11.3.2 Boehringer Ingelheim GmbH Business Overview 11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction 11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.3.5 Boehringer Ingelheim GmbH Recent Development 11.4 Eli Lilly and Company 11.4.1 Eli Lilly and Company Company Details 11.4.2 Eli Lilly and Company Business Overview 11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction 11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.4.5 Eli Lilly and Company Recent Development 11.5 Merck KgaA 11.5.1 Merck KgaA Company Details 11.5.2 Merck KgaA Business Overview 11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction 11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.5.5 Merck KgaA Recent Development 11.6 Amgen, Inc. 11.6.1 Amgen, Inc. Company Details 11.6.2 Amgen, Inc. Business Overview 11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction 11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.6.5 Amgen, Inc. Recent Development 11.7 AstraZeneca PLC 11.7.1 AstraZeneca PLC Company Details 11.7.2 AstraZeneca PLC Business Overview 11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction 11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.7.5 AstraZeneca PLC Recent Development 11.8 Actelion Pharmaceuticals Ltd. 11.8.1 Actelion Pharmaceuticals Ltd. Company Details 11.8.2 Actelion Pharmaceuticals Ltd. Business Overview 11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction 11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.8.5 Actelion Pharmaceuticals Ltd. Recent Development 11.9 Shire PLC 11.9.1 Shire PLC Company Details 11.9.2 Shire PLC Business Overview 11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction 11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.9.5 Shire PLC Recent Development 11.10 AbbVie, Inc. 11.10.1 AbbVie, Inc. Company Details 11.10.2 AbbVie, Inc. Business Overview 11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction 11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.10.5 AbbVie, Inc. Recent Development 11.11 Biocon Ltd. 11.11.1 Biocon Ltd. Company Details 11.11.2 Biocon Ltd. Business Overview 11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction 11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.11.5 Biocon Ltd. Recent Development 11.12 BioMarin Pharmaceutical, Inc. 11.12.1 BioMarin Pharmaceutical, Inc. Company Details 11.12.2 BioMarin Pharmaceutical, Inc. Business Overview 11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction 11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.12.5 BioMarin Pharmaceutical, Inc. Recent Development 11.13 Bristol-Myers Squibb Company 11.13.1 Bristol-Myers Squibb Company Company Details 11.13.2 Bristol-Myers Squibb Company Business Overview 11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction 11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.13.5 Bristol-Myers Squibb Company Recent Development 11.14 Cipla, Inc. 11.14.1 Cipla, Inc. Company Details 11.14.2 Cipla, Inc. Business Overview 11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction 11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.14.5 Cipla, Inc. Recent Development 11.15 CymaBay Therapeutics, Inc. 11.15.1 CymaBay Therapeutics, Inc. Company Details 11.15.2 CymaBay Therapeutics, Inc. Business Overview 11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction 11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) 11.15.5 CymaBay Therapeutics, Inc. Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
List of Tables Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Lysosomal Storage Diseases Table 3. Key Players of Diabetes Table 4. Key Players of Obesity Table 5. Key Players of Inherited Metabolic Disorders Table 6. Key Players of Hypercholesterolemia Table 7. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global Metabolic Disorder Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global Metabolic Disorder Therapeutics Market Size by Regions (2016-2021) & (US$ Million) Table 10. Global Metabolic Disorder Therapeutics Market Share by Regions (2016-2021) Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 12. Global Metabolic Disorder Therapeutics Market Share by Regions (2022-2027) Table 13. Metabolic Disorder Therapeutics Market Trends Table 14. Metabolic Disorder Therapeutics Market Drivers Table 15. Metabolic Disorder Therapeutics Market Challenges Table 16. Metabolic Disorder Therapeutics Market Restraints Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2016-2021) & (US$ Million) Table 18. Global Metabolic Disorder Therapeutics Market Share by Players (2016-2021) Table 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2020) Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2020 Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2016-2021) Table 22. Key Players Headquarters and Area Served Table 23. Key Players Metabolic Disorder Therapeutics Product Solution and Service Table 24. Date of Enter into Metabolic Disorder Therapeutics Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2016-2021) Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million) Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million) Table 30. Global Metabolic Disorder Therapeutics Market Size Share by Application (2016-2021) & (US$ Million) Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2016-2021) Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million) Table 33. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million) Table 34. North America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 35. North America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 36. North America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 37. North America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 38. North America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 39. North America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 40. Europe Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 41. Europe Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 42. Europe Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 43. Europe Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 44. Europe Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 45. Europe Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 46. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 47. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 48. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 49. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 50. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2016-2021) & (US$ Million) Table 51. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2022-2027) & (US$ Million) Table 52. Latin America Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 53. Latin America Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 54. Latin America Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 55. Latin America Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 56. Latin America Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 57. Latin America Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 58. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2016-2021) (US$ Million) Table 59. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Type (2022-2027) & (US$ Million) Table 60. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2016-2021) (US$ Million) Table 61. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Application (2022-2027) & (US$ Million) Table 62. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2016-2021) & (US$ Million) Table 63. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2022-2027) & (US$ Million) Table 64. Novo Nordisk A/S Company Details Table 65. Novo Nordisk A/S Business Overview Table 66. Novo Nordisk A/S Metabolic Disorder Therapeutics Product Table 67. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 68. Novo Nordisk A/S Recent Development Table 69. Sanofi S.A. Company Details Table 70. Sanofi S.A. Business Overview Table 71. Sanofi S.A. Metabolic Disorder Therapeutics Product Table 72. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 73. Sanofi S.A. Recent Development Table 74. Boehringer Ingelheim GmbH Company Details Table 75. Boehringer Ingelheim GmbH Business Overview Table 76. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product Table 77. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 78. Boehringer Ingelheim GmbH Recent Development Table 79. Eli Lilly and Company Company Details Table 80. Eli Lilly and Company Business Overview Table 81. Eli Lilly and Company Metabolic Disorder Therapeutics Product Table 82. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 83. Eli Lilly and Company Recent Development Table 84. Merck KgaA Company Details Table 85. Merck KgaA Business Overview Table 86. Merck KgaA Metabolic Disorder Therapeutics Product Table 87. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 88. Merck KgaA Recent Development Table 89. Amgen, Inc. Company Details Table 90. Amgen, Inc. Business Overview Table 91. Amgen, Inc. Metabolic Disorder Therapeutics Product Table 92. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 93. Amgen, Inc. Recent Development Table 94. AstraZeneca PLC Company Details Table 95. AstraZeneca PLC Business Overview Table 96. AstraZeneca PLC Metabolic Disorder Therapeutics Product Table 97. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 98. AstraZeneca PLC Recent Development Table 99. Actelion Pharmaceuticals Ltd. Company Details Table 100. Actelion Pharmaceuticals Ltd. Business Overview Table 101. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 102. Actelion Pharmaceuticals Ltd. Recent Development Table 103. Shire PLC Company Details Table 104. Shire PLC Business Overview Table 105. Shire PLC Metabolic Disorder Therapeutics Product Table 106. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 107. Shire PLC Recent Development Table 108. AbbVie, Inc. Company Details Table 109. AbbVie, Inc. Business Overview Table 110. AbbVie, Inc. Metabolic Disorder Therapeutics Product Table 111. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 112. AbbVie, Inc. Recent Development Table 113. Biocon Ltd. Company Details Table 114. Biocon Ltd. Business Overview Table 115. Biocon Ltd. Metabolic Disorder Therapeutics Product Table 116. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 117. Biocon Ltd. Recent Development Table 118. BioMarin Pharmaceutical, Inc. Company Details Table 119. BioMarin Pharmaceutical, Inc. Business Overview Table 120. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product Table 121. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 122. BioMarin Pharmaceutical, Inc. Recent Development Table 123. Bristol-Myers Squibb Company Company Details Table 124. Bristol-Myers Squibb Company Business Overview Table 125. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product Table 126. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 127. Bristol-Myers Squibb Company Recent Development Table 128. Cipla, Inc. Company Details Table 129. Cipla, Inc. Business Overview Table 130. Cipla, Inc. Metabolic Disorder Therapeutics Product Table 131. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 132. Cipla, Inc. Recent Development Table 133. CymaBay Therapeutics, Inc. Company Details Table 134. CymaBay Therapeutics, Inc. Business Overview Table 135. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product Table 136. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2016-2021) & (US$ Million) Table 137. CymaBay Therapeutics, Inc. Recent Development Table 138. Research Programs/Design for This Report Table 139. Key Data Information from Secondary Sources Table 140. Key Data Information from Primary Sources List of Figures Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2020 VS 2027 Figure 2. Lysosomal Storage Diseases Features Figure 3. Diabetes Features Figure 4. Obesity Features Figure 5. Inherited Metabolic Disorders Features Figure 6. Hypercholesterolemia Features Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2027 Figure 8. Oral Case Studies Figure 9. Parenteral Case Studies Figure 10. Others Case Studies Figure 11. Metabolic Disorder Therapeutics Report Years Considered Figure 12. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 13. Global Metabolic Disorder Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global Metabolic Disorder Therapeutics Market Share by Regions: 2020 VS 2027 Figure 15. Global Metabolic Disorder Therapeutics Market Share by Regions (2022-2027) Figure 16. Global Metabolic Disorder Therapeutics Market Share by Players in 2020 Figure 17. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2020 Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2020 Figure 19. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2016-2021) Figure 20. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2022-2027) Figure 21. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 22. North America Metabolic Disorder Therapeutics Market Share by Type (2016-2027) Figure 23. North America Metabolic Disorder Therapeutics Market Share by Application (2016-2027) Figure 24. North America Metabolic Disorder Therapeutics Market Share by Country (2016-2027) Figure 25. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Europe Metabolic Disorder Therapeutics Market Share by Type (2016-2027) Figure 29. Europe Metabolic Disorder Therapeutics Market Share by Application (2016-2027) Figure 30. Europe Metabolic Disorder Therapeutics Market Share by Country (2016-2027) Figure 31. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. France Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Nordic Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Type (2016-2027) Figure 39. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Application (2016-2027) Figure 40. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Region (2016-2027) Figure 41. China Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. India Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Latin America Metabolic Disorder Therapeutics Market Share by Type (2016-2027) Figure 49. Latin America Metabolic Disorder Therapeutics Market Share by Application (2016-2027) Figure 50. Latin America Metabolic Disorder Therapeutics Market Share by Country (2016-2027) Figure 51. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Type (2016-2027) Figure 55. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Application (2016-2027) Figure 56. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Country (2016-2027) Figure 57. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. UAE Metabolic Disorder Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 61. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 62. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 63. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 64. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 65. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 66. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 67. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 68. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 69. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 70. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 71. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 72. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 73. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 74. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2016-2021) Figure 75. Bottom-up and Top-down Approaches for This Report Figure 76. Data Triangulation Figure 77. Key Executives Interviewed
Novo Nordisk A/S Sanofi S.A. Boehringer Ingelheim GmbH Eli Lilly and Company Merck KgaA Amgen, Inc. AstraZeneca PLC Actelion Pharmaceuticals Ltd. Shire PLC AbbVie, Inc. Biocon Ltd. BioMarin Pharmaceutical, Inc. Bristol-Myers Squibb Company Cipla, Inc. CymaBay Therapeutics, Inc.
Electronic design automation (EDA), also referred to as electronic computer-aided design (ECAD), ... Read More
Maritime tourism refers to those recreational activities which involve travel away from one’s p ... Read More
Maritime tourism refers to those recreational activities which involve travel away from one’s p ... Read More
An Environmentally Friendly Cable is an environmentally-benign electric wire/cable that uses envi ... Read More